Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 45 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
441 18.6 months Metastatic breast cancer 5 Chemotherapy
Loyola University Chicago Stritch School of Medicine United States 8/2008
Treatment Details: Patients: This phase III study involved 529 women with advanced breast cancer. These patients previously received anthracycline treatment. The median age was 53, ranging from 26 to 83 year
 
442 18.6 months Advanced and recurrent NSCLC 3 Immunotherapy
Chiba University Japan 2/2009
Treatment Details: Patients: This study involved 17 patients with advanced and recurrent non-small cell lung cancer. There were five women and twelve men, ranging in age from 43 to 73 years. Treatment: P
 
443 18.6 months Metastatic Colorectal Cancer 4 Chemotherapy
University Hospital Gasthuisberg Belgium 4/2009
Treatment Details: Patients: The patients in this study were separated into 2 treatment groups (arms). Arm A involved 599 patients, 61.6% of whom were male. Arm B also involved 599, 59.4% of whom were male.
 
444 18.6 months Hormone refractory prostate cancer 4 Chemotherapy
Georges Pompidou European Hospital France 5/2005
Treatment Details: Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group A had 44 men (median age 68) with hormonal-resistant prostate cancer. For all patients, metasta
 
445 18.6 months Newly diagnosed GBM 4 Chemotherapy
Radiation
Istituto Nazionale Neurologico Carlo Besta Italy 12/2002
Treatment Details: Patients: This study involved 30 newly diagnosed patients with glioblastoma. The patients were divided into two groups (A and B) of 15 patients each. Treatment: Patients in Group A recei
 
446 18.6 months Metastatic, castration-resistant prostate cancer 4 Chemotherapy
Royal Marsden Hospital United Kingdom 5/2012
Treatment Details: Patients: This phase 2 study involved 108 metastatic castration-resistant prostate cancer patients with a median age of 71 years. Treatment: Patients were treated with the chemotherapy
 
447 18.5 months GBM 3 Biologic therapy
Radiation
Institut Claudius Regaud France 4/2013
Treatment Details: Patients: This phase 2 study involved 27 newly diagnosed glioblastoma patients who had not been previously treated. The median patient age was 59 years and 18 were male. Treatment: Pat
 
448 18.5 months Newly diagnosed GBM 5 Biologic therapy
Chemotherapy
Radiation
Surgery
Department of Surgery, Duke University Medical Center United States 3/2002
Treatment Details: Patients: This Phase II study involved 33 newly diagnosed glioma patients comprised of 27 glioblastoma multiform patients, 4 anaplastic astrocytoma patients, and 2 anaplastic oligodendroglio
 
449 18.4 months Metastatic breast cancer 5 Chemotherapy
Oncology and Hematology Associates United States 1/2003
Treatment Details: Patients: This Phase II trial involved 155 patients with metastatic breast cancer. Treatment: The treatment involved administration of three drugs paclitaxel (taxol) 5-fluorouracil (adr
 
450 18.4 months Hormone refractory prostate cancer 4 Chemotherapy
Georges Pompidou European Hospital France 5/2005
Treatment Details: Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group B had 42 men (median age 68) with hormonal-resistant prostate cancer. In 39 patients, metastati
 
Page 45 of 187  | Previous Page  | Next Page